Format

Send to

Choose Destination
Vaccine. 2001 Feb 28;19(15-16):2118-26.

Potency of clinical group B streptococcal conjugate vaccines.

Author information

1
Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. lpaoletti@channing.harvard.edu

Abstract

The potency of clinical group B streptococcal (GBS) capsular polysaccharide-protein conjugate vaccines has been assessed with use of a mouse maternal vaccination-neonatal pup challenge model of GBS disease. Two of the three conjugated GBS vaccines bottled as liquid preparations showed a potency reduction from 100% to < or = 50% in 3 years; whereas all six vaccines bottled as lyophilized preparations with sucrose excipient exhibited no loss of potency during the same span of time. A reconstituted GBS conjugate vaccine remained potent and antigenically intact after 31 days' storage at 2-8 degrees C. These data suggest that lyophilization in the presence of sucrose extends the potency of GBS conjugate vaccines.

PMID:
11228384
DOI:
10.1016/s0264-410x(00)00437-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center